Nephrology & Internal Medicine. Immunothrombosis incl DIC. ISTH Member. No Conflicts of Interest. Views my own etc
Sydney, Australia
Joined September 2012
- Tweets25K
- Following3.2K
- Followers32.6K
- Likes124K
Pinned Tweet
“Death in Hamburg” by @RichardEvans36. A book written in 1987for our COVID age. The title, a reference to Thomas Mann's Death in Venice, this is a review of one of the best books I've ever read. 5/5 stars. 🧵 penguinrandomhouse.com/books…
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
SARS-CoV-2 community spread in Aotearoa NZ began with Omicron in January 2022 (the 2021-22 data point on this chart).
ED presentations jumped up, and they kept increasing (even though the SARS-2 waves got smaller after mid-22).
This is a growing burden of SARS-2 chronic harm.
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
"Korea makes COVID-19 vaccination part of routine national immunization program"
KDCA says COVID-19 continues producing variants that can evade immunity, while people 65+ account for 63% of hospitalisations. It is shifting to routine vaccination to protect high-risk groups.
ALT An article screenshot from the Korea Biomedical Review titled "Korea makes Covid-19 vaccination part of routine national immunization program". The piece is written by Kwak Sung-sun and was published on 2026.09.17. The main image shows hands in a laboratory setting using a syringe to draw liquid from a small vaccine vial. The caption below states that the Korea Disease Control and Prevention Agency announced that Covid-19 vaccinations will join the routine national program starting Oct. 12 for individuals aged 70 and older, immunocompromised people, and other eligible high-risk groups.
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
「もう終わったこと」
「私は大丈夫」
「若い人たちは安全」
「マスクなんて必要ない」
「ただの風邪」
「風土病でしかない」
「子どもは軽症で済む」
コロナを無視することは命に関わります。
作 @YouAreLobbyLud /訳 @OfficeBALES
#第15波ですマスクしましょう😷
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
A slightly more personal post than usual.
I’ve always believed that scientific disagreement can be discussed without turning into insults, mockery or personal attacks.
Over the last few days, I’ve realised that this seems to have become much harder in some parts of this community.
And honestly, I find that sad.
(1/9) 🧵
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
The @ISLCPAIS conference website was hacked more than twice including during the event. We received massive amounts of criticism online, and more than once @miketweetchap received threats at his home address, simply for trying to bring people together.
Michael, you did nothing wrong.
You poured your heart and soul into this conference, while carrying the additional reality of being a Long Covid patient yourself. I saw how much work, energy and care you put into making this happen, and I honestly think what you accomplished was tremendous.
Those of us working in this field are fighting on so many fronts. We are fighting #COVID and #LongCovid denial and dismissal, while also having to deal with radical voices within our own community attacking the very people who are trying to move the field forward. It is exhausting.
But for the last days, we saw what can happen when people come together despite all of that. Scientists, physicians and patient advocates in the same room, sharing ideas, building collaborations and trying to find better answers for patients.
So please don't let the attacks make you question why you did this. You did it because you care. And you created something that brought people together when we desperately need more of that.
I’m incredibly grateful to be part of this and I hope you take a moment to be proud of what you accomplished. ❤️
I have received criticism and even a threat at my home address for organizing the @ISLCPAIS conference. I pored my heart and soul into it because I believe boosting collaboration and bringing together the bright minds is fundamental for speeding up the process. What did I do wrong? It’s as genuine question after self reflection…
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
The 2026 Amsterdam ISLC-PAIS Conference Abstract Book is now officially online. The Abstract Book is exclusively available to registered in-person attendees. Please log in and visit the Your Access section in the attendee portal to access it.
On behalf of our chair @RobWust we thank all researchers, clinicians, healthcare professionals and experts by experience who submitted their work on Long COVID, ME/CFS and Post-Acute Infection Syndromes (PAIS).
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
I do believe science can unite safely & accomplish 5 months worth of time into 4 days. Whatever it takes to get this subject matter to the next generation of scientists & doctors who have been encouraged to study #LongCovid.
Ideas are priceless.
Could Mitochondrial Transplantation Open New Research Avenues?
At #ISLCPAIS, Professor @PutrinoLab discusses pioneering research into mitochondrial transplantation, an experimental approach aimed at restoring cellular energy.
#LongCOVIDTheAnswers #longcovid
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
#ISLCPAIS2026 abstract review.
My thoughts on abstract 2
One of my fav studies which basically replicates @VirusesImmunity bigger studies in transfer of IgG from
patients with #longcovid to mice.
This study provides further evidence for an immune-mediated mechanism of pain in Long COVID, showing that patient-derived IgG targets peripheral sensory neurons in vivo and ex vivo. These findings strengthen the rationale for testing immunomodulatory approaches such as IVIG in carefully designed clinical trials.
Importantly, funding strategies should not focus exclusively on viral persistence: the growing evidence for pathogenic autoantibodies and immune-mediated neuronal dysfunction makes immunomodulation a parallel, high-priority therapeutic avenue that warrants properly powered clinical trials. I’m surprised this is still not on the priority list
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Thank you so much to everyone for the kind messages and support 🥹! Happy to share that I won the 2026 Young Investigator award @ISLC_PAIS and also met the amazing Dr. Funmi Okunola
@longcovidanswer
We will keep fighting and we won't give up! 💪 #LongCovid #MECFS #PAIS
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
ISLC-PAIS 2026 Young Investigator Award
Huge congratulations to Dr. @DaniBeckman on receiving the ISLC-PAIS 2026 Young Investigator Award, recognition of her outstanding research into Long COVID and post-acute infection syndromes.
#ISLCPAIS #LongCOVID #PAIS #MEcfs
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Thanks to the great team of @aranet_home our production staff can monitor each area of the venue. Here’s the history of today.
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Important review about #POTS from my colleague @satish_r_raj, who is part of our @ISLC_PAIS society and presenting in our meeting this Friday.
#LongCovid
#PosturalOrthostaticTachycardiaSyndrome (POTS) is a chronic autonomic disorder defined by orthostatic symptoms with a sustained heart rate increase within 10 minutes of standing or head-up tilt, without orthostatic hypotension.
🔗 ja.ma/4zzP3Kn
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
We’ve been building this society together for years and today we finally meet in Amsterdam! 🧡
The inaugural ISLC-PAIS Conference starts today with 4 days of science, collaboration and new connections to fight for #LongCOVID and #PAIS.
Welcome to #ISLCPAIS2026! 🔬
@ISLCPAIS
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Hello, Amsterdam! 🇳🇱🧡
So excited to be here for the first ISLC-PAIS Conference and to finally see so many colleagues, collaborators & friends in person!
Four days of #LongCOVID and #PAIS science, discussions and new ideas ahead. 🧠🔬
#ISLCPAIS2026
We’ve been building this society together for years and today we finally meet in Amsterdam! 🧡
The inaugural ISLC-PAIS Conference starts today with 4 days of science, collaboration and new connections to fight for #LongCOVID and #PAIS.
Welcome to #ISLCPAIS2026! 🔬
@ISLCPAIS
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Only one week to go until the 2026 Amsterdam ISLC-PAIS Conference brings together more than 300 clinicians, scientists, early-career researchers and patient advocates, all committed to advancing our understanding of Long COVID and other Post-Acute Infection Syndromes.
With more than 100 scientific sessions, the conference will cover the latest research, clinical insights and developments across the field.
To make the key takeaways accessible beyond the conference itself, we are organising the Patient Recap Livestream Session. A dedicated session that translates the most relevant conference insights into clear and accessible information for patients.
islc-pais.org/program/patien…
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Outside a Sydney emergency department this week. Perhaps the penny has dropped that staff keep falling ill and going off sick, and mitigation is possible. Surprising % of patients and staff complying, too.
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Take a front-row seat to the 2026 #Amsterdam ISLC-PAIS Conference with on-demand access to more than 100 recorded scientific and clinical presentations.
At a fraction of the costs, this is the International #LongCOVID #MECFS #PAIS Conference you can attend anytime, whereever you are and at a fraction of the costs.
GET VIDEO ON DEMAND TODAY!
You can miss your peers, but you can't miss out on the latest science.
islc-pais.org/vod
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
We have family member who has reactivated TB meningitis post covid (several infections). Tuberculoma. Initially diagnosed as brain cancer…so treatment time lost & now terminal.
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
About to miss #ISLCPAIS2026 in Amsterdam? You don’t have to miss the science!
🎥 100+ recorded talks
🔬 Latest research on #LongCOVID #MECFS and #PAIS
🌍 Watch anywhere, anytime
💶 Lower cost than attending in person
Get Video on Demand access today:
islc-pais.org/vod
Dr Satoshi Akima FRACP 『秋間聰』 retweeted
Xocova Tablets 25 mg (Ensitrelvir Fumaric Acid, Shionogi)
ゾコーバ錠25mg（エンシトレルビル フマル酸、塩野義製薬）
ゾコーバはSARS-CoV-2の3CLプロテアーゼを阻害する抗ウイルス薬で、新型コロナウイルス感染症の治療に用いる。
従来は12歳以上の小児と成人に用法・用量が設定されていたが、6月19日に6歳以上かつ体重20kg以上の小児にも対象が拡大された。
25mg錠はこの小児用量への対応に伴う剤形追加で、薬価は1錠2,575.40円。小児加算5％が適用され、薬価維持制度の対象となる。
ピーク時の予測は投与患者278人、販売額0.13億円。
Xocova is a SARS-CoV-2 3CL protease inhibitor for treating COVID-19. Dosing was expanded on June 19 to children aged ≥6 years weighing ≥20 kg, in addition to patients aged ≥12 years. The new 25-mg tablet supports pediatric dosing and is priced at ¥2,575.40 per tablet.
#小児用量 #新型コロナウイルス感染症 #3CLプロテアーゼ阻害剤
#PediatricDosing #COVID19 #3CLProteaseInhibitor
mixonline.jp/tabid55.html?ar…
At last, a pill that can prevent COVID after exposure to infected people
感染者との接触後にCOVID-19を防ぐ初の飲み薬
抗ウイルス薬エンシトレルビル（ゾコーバ）が、家庭内でSARS-CoV-2に暴露した人のCOVID-19発症を防ぐ可能性を示した。
2,000人超を対象にした国際試験では、同居人の発症から72時間以内に5日間服用した人の発症率は約3%で、プラセボ群の約9%より低かった。
感染そのものも、エンシトレルビル群で14.0%、プラセボ群で21.5%と少なかった。忍容性はおおむね良好だった。
日本では曝露後予防として承認されており、高齢者、基礎疾患のある人、免疫抑制中の人、医療従事者などで有用性が期待される。
Ensitrelvir, marketed as Xocova, is the first antiviral pill shown to prevent COVID-19 after household exposure. In a trial of more than 2,000 contacts, five days of treatment within 72 hours cut symptomatic illness from about 9% to 3%. It may help protect people at high risk.
nature.com/articles/d41586-0…
#COVID19 #エンシトレルビル #曝露後予防
#COVID19 #ensitrelvir #postexposureprophylaxis
